10x Genomics, Inc. TXG

About 10x Genomics, Inc. (TXG): stock profile, AI score and financials

10x Genomics, Inc. (TXG) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TXG at 39.9/100 on a composite quality score built from its SEC filings, placing it at rank #2,119 of 2,925 stocks — the bottom half of the AI-ranked universe. TXG scores in the top quartile across earnings quality (78.6). Areas of concern include balance sheet strength (19.2) and profitability (20.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 10.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), 10x Genomics, Inc. reports quarterly revenue of $151.0M, net income of $-17.9M, an operating margin of -13.0%. Top institutional holders of TXG by reported 13-F value include FMR, BlackRock, ARK Investment Management, based on the most recent SEC filings. TXG trades on the Nasdaq exchange and files with the SEC under CIK 1770787. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TXG daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for 10x Genomics, Inc. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1770787 →